Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2019-11-07. Its lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. Its second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The firm's new lead program is the Investigator-sponsored Phase I/II trial of a pan-NOS Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer.
Follow-Up Questions
Galera Therapeutics Inc의 CEO는 누구입니까?
Dr. J. Mel Sorensen은 2012부터 회사에 합류한 Galera Therapeutics Inc의 Chairman of the Board입니다.
GRTX 주식의 가격 성능은 어떻습니까?
GRTX의 현재 가격은 $0.024이며, 전 거래일에 decreased 0% 하였습니다.
Galera Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Galera Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Galera Therapeutics Inc의 시가총액은 얼마입니까?
Galera Therapeutics Inc의 현재 시가총액은 $1.8M입니다
Galera Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 Galera Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 4명의 보유, 1명의 매도, 그리고 0명의 강력한 매도를 포함합니다
